Advanced glycation endproducts in ageing and Alzheimer's disease

Brain Res Brain Res Rev. 1997 Feb;23(1-2):134-43. doi: 10.1016/s0165-0173(96)00016-1.


Accumulation of advanced glycation endproducts (AGE) in the brain is a feature of ageing and degeneration, especially in Alzheimer's disease (AD). Increased AGE levels explain many of the neuropathological and biochemical features of AD such as extensive protein crosslinking (beta-amyloid and MAP-tau), oxidative stress and neuronal cell death. Oxidative stress and AGEs initiate a positive feedback loop, where normal age-related changes develop into a pathophysiological cascade. Combined intervention using antioxidants, metal chelators, anti-inflammatory drugs and AGE-inhibitors may be a promising neuroprotective strategy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aging / metabolism*
  • Alzheimer Disease / metabolism*
  • Animals
  • Cardiovascular Diseases / metabolism
  • Glycation End Products, Advanced / metabolism*
  • Humans


  • Glycation End Products, Advanced